|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Srivatanakul P, Sriplung H and Deerasamee
S: Epidemiology of liver cancer: An overview. Asian Pac J Cancer
Prev. 5:118–125. 2004.PubMed/NCBI
|
|
3
|
Bosetti C, Turati F and La Vecchia C:
Hepatocellular carcinoma epidemiology. Best Pract Res Clin
Gastroenterol. 28:753–770. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zuo TT, Zheng RS, Zhang SW, Zeng HM and
Chen WQ: Incidence and mortality of liver cancer in China in 2011.
Chin J Cancer. 34:508–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gish RG, Finn RS and Marrero JA: Extending
survival with the use of targeted therapy in the treatment of
hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 9 (Suppl
2):S1–S24. 2013.
|
|
6
|
Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC,
Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW and Kuo WH: Current
systemic treatment of hepatocellular carcinoma: A review of the
literature. World J Hepatol. 7:1412–1420. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsimberidou AM: Targeted therapy in
cancer. Cancer Chemother Pharmacol. 76:1113–1132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peck JW, Oberst M, Bouker KB, Bowden E and
Burbelo PD: The RhoA-binding protein, rhophilin-2, regulates actin
cytoskeleton organization. J Biol Chem. 277:43924–43932. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Danussi C, Akavia UD, Niola F, Jovic A,
Lasorella A, Pe'er D and Iavarone A: RHPN2 drives mesenchymal
transformation in malignant glioma by triggering RhoA activation.
Cancer Res. 73:5140–5150. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Qian H, Deng X, Huang ZW, Wei J, Ding CH,
Feng RX, Zeng X, Chen YX, Ding J, Qiu L, et al: An HNF1α-regulated
feedback circuit modulates hepatic fibrogenesis via the crosstalk
between hepatocytes and hepatic stellate cells. Cell Res.
25:930–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zeng X, Lin Y, Yin C, Zhang X, Ning BF,
Zhang Q, Zhang JP, Qiu L, Qin XR, Chen YX and Xie WF: Recombinant
adenovirus carrying the hepatocyte nuclear factor-1alpha gene
inhibits hepatocellular carcinoma xenograft growth in mice.
Hepatology. 54:2036–2047. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu J, Lichtenberg T, Hoadley KA, Poisson
LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee
AV, et al: An integrated TCGA pan-cancer clinical data resource to
drive high-quality survival outcome analytics. Cell.
173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garcia DM, Baek D, Shin C, Bell GW,
Grimson A and Bartel DP: Weak seed-pairing stability and high
target-site abundance decrease the proficiency of lsy-6 and other
microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Agarwal V, Bell GW, Nam J-W and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar
|
|
17
|
Hofman F: Immunohistochemistry. Current
protocols in immunology. 49:21.24. 21–21.24. 23. 2002.
|
|
18
|
Quail DF, Bowman RL, Akkari L, Quick ML,
Schuhmacher AJ, Huse JT, Holland EC, Sutton JC and Joyce JA: The
tumor microenvironment underlies acquired resistance to CSF-1R
inhibition in gliomas. Science. 352:aad30182016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roehm NW, Rodgers GH, Hatfield SM and
Glasebrook AL: An improved colorimetric assay for cell
proliferation and viability utilizing the tetrazolium salt XTT. J
Immunol Methods. 142:257–265. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gerlier D and Thomasset N: Use of MTT
colorimetric assay to measure cell activation. J Immunol Methods.
94:57–63. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berridge MV, Tan AS, McCoy KD and Wang R:
The biochemical and cellular basis of cell proliferation assays
that use tetrazolium salts. Biochemica. 4:14–19. 1996.
|
|
24
|
Weichert H, Blechschmidt I, Schröder S and
Ambrosius H: The MTT-assay as a rapid test for cell proliferation
and cell killing: Application to human peripheral blood lymphocytes
(PBL). Allerg Immunol (Leipz). 37:139–144. 1991.PubMed/NCBI
|
|
25
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Korpal M and Kang Y: The emerging role of
miR-200 family of microRNAs in epithelial-mesenchymal transition
and cancer metastasis. RNA Biol. 5:115–119. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng H, Zhang L, Cogdell DE, Zheng H,
Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR and Zhang W:
Circulating plasma MiR-141 is a novel biomarker for metastatic
colon cancer and predicts poor prognosis. PLoS One. 6:e177452011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Du Y, Xu Y, Ding L, Yao H, Yu H, Zhou T
and Si J: Down-regulation of miR-141 in gastric cancer and its
involvement in cell growth. J Gastroenterol. 44:556–561. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Van Jaarsveld MT, Helleman J, Boersma AW,
van Kuijk PF, van Ijcken WF, Despierre E, Vergote I, Mathijssen RH,
Berns EM, Verweij J, et al: miR-141 regulates KEAP1 and modulates
cisplatin sensitivity in ovarian cancer cells. Oncogene.
32:4284–4293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tejero R, Navarro A, Campayo M, Viñolas N,
Marrades RM, Cordeiro A, Ruíz-Martínez M, Santasusagna S, Molins L,
Ramirez J and Monzó M: miR-141 and miR-200c as markers of overall
survival in early stage non-small cell lung cancer adenocarcinoma.
PLoS One. 9:e1018992014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Neves R, Scheel C, Weinhold S, Honisch E,
Iwaniuk KM, Trompeter HI, Niederacher D, Wernet P, Santourlidis S
and Uhrberg M: Role of DNA methylation in miR-200c/141 cluster
silencing in invasive breast cancer cells. BMC Res Notes.
3:2192010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li A, Omura N, Hong SM, Vincent A, Walter
K, Griffith M, Borges M and Goggins M: Pancreatic cancers
epigenetically silence SIP1 and hypomethylate and overexpress
miR-200a/200b in association with elevated circulating miR-200a and
miR-200b levels. Cancer Res. 70:5226–5237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xia H, Ng SS, Jiang S, Cheung WK, Sze J,
Bian XW, Kung HF and Lin MC: miR-200a-mediated downregulation of
ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma
cell growth, migration and invasion. Biochem Biophys Res Commun.
391:535–541. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mateescu B, Batista L, Cardon M, Gruosso
T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P,
Sastre-Garau X and Mechta-Grigoriou F: miR-141 and miR-200a act on
ovarian tumorigenesis by controlling oxidative stress response. Nat
Med. 17:1627–1635. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lu Y, Lu J, Li X, Zhu H, Fan X, Zhu S,
Wang Y, Guo Q, Wang L, Huang Y, et al: MiR-200a inhibits
epithelial-mesenchymal transition of pancreatic cancer stem cell.
BMC Cancer. 14:852014. View Article : Google Scholar : PubMed/NCBI
|
